A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

Inclusion Criteria for Molecular Prescreening: The following inclusion criteria must be met for a participant to be eligible to undergo molecular tumor prescreening: * Chinese male or female participant with age ≥18 years at the time of informed consent. * Histologically- or cytologically-confirmed colorectal cancer (CRC) that is metastatic. * Eligible to receive cetuximab per Chinese approved label with regard to tumor Rat Sarcoma Viral Oncogene Homologue (RAS) mutation status (i.e. approved for Rat Sarcoma Viral Oncogene Homologue Wild Type(RAS wt) status). * Able to provide a sufficient amount of representative tumor specimen for central prospective laboratory testing of B-RAF Proto-oncogene, Serine/threonine Kinase (BRAF) mutation status and also retrospective RAS wt status and Microsatellite Instability (MSI) testing. Inclusion Criteria for Treatment Period: The following inclusion criteria must be met for a participant to be eligible for this study: * Chinese male or female participant with age ≥18 years at time of informed consent. * Histologically or cytologically confirmed CRC that is metastatic and unresectable at time of study entry (i.e. not suitable for complete surgical resection at screening). * Presence of a BRAF V600E mutation in tumor tissue previously determined by a local assay at any time before screening or by the central laboratory. NOTE: Other protocol defined Inclusion criteria may apply Exclusion Criteria for Molecular Prescreening: Participa…